- RecruitingPHASE2
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
This study is testing a new drug called Tideglusib for a heart condition called Arrhythmogenic Cardiomyopathy (ACM). It aims to see if the drug can help improve the condition by targeting specific pathways in the heart. The study is in its early stages.
For: Arrhythmogenic Cardiomyopathy · Arrhythmogenic Right Ventricular CardiomyopathyCanada - RecruitingPHASE2, PHASE3
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
This study is looking into a medicine called Tideglusib for children and young people aged 6 to 45 with a muscle condition called Congenital or Childhood Myotonic Dystrophy (DM1). It aims to see how safe and effective the medicine is.
For: Congenital Myotonic DystrophyUnited States · Australia · Canada